Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 19/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 13/20 | 0.36 |
| ▸ | PGR | P06401 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293399 | 0.89 | NR3C1 (0.47) | NR3C1NR3C2PGR | |
| SCHEMBL291686 | 0.81 | NR3C1 (0.49) | NR3C1NR3C2PGR | |
| SCHEMBL293735 | 0.79 | NR3C1 (0.45) | NR3C1NR3C2PGR | |
| SCHEMBL4157801 | 0.79 | NR3C1 (0.46) | NR3C1NR3C2PGREGFRFGFR1 | |
| SCHEMBL452415 | 0.79 | NR3C1 (0.49) | NR3C1NR3C2PGR | |
| SCHEMBL292833 | 0.77 | NR3C1 (0.48) | NR3C1NR3C2PGR | |
| SCHEMBL293742 | 0.76 | NR3C1 (0.57) | NR3C1NR3C2PGR | |
| SCHEMBL4157784 | 0.75 | NR3C1 (0.35) | NR3C1NR3C2PGR | |
| SCHEMBL4162966 | 0.73 | NR3C1 (0.55) | NR3C1NR3C2PGR | |
| SCHEMBL292921 | 0.72 | NR3C1 (0.44) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | claimed |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | US | claimed |
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 71/4885 |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, MC2R, NR3C2 | NR3C1 1/4885NR3C2 3/4885PGR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.